MIRA Pharmaceuticals, Inc. (MIRA) Income Statement
MIRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMIRA revenue and net income
MIRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MIRA quarterly EPS vs estimates
MIRA Pharmaceuticals beat the analyst EPS estimate in 4 of the last 6 quarters. Next report: November 12, 2026.
MIRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $8.5M | — | — | — |
| Gross profit | — | — | −$8.5M | — | — | — |
| Research & development | $1.7M | $3.3M | $1.6M | $2.4M | $684,447 | $14,647 |
| Sales, general & admin | $8.8M | $4.7M | $7.0M | $3.0M | $770,115 | $158,946 |
| Total operating expenses | $10.5M | $8.0M | $8.5M | $7.0M | $2.2M | $67,629 |
| Operating income | −$10.5M | −$8.0M | −$8.5M | −$7.0M | −$2.2M | −$67,629 |
| Interest income | $98,911 | $165,669 | — | — | — | — |
| Interest expense | — | $165,669 | $3.5M | $10,250 | $24,374 | $364 |
| Income before taxes | −$10.4M | −$7.9M | −$12.0M | −$7.1M | −$2.2M | −$67,993 |
| Income taxes | — | — | −$8,526 | −$7,048 | −$2,152 | −$203 |
| Net income | −$10.4M | −$7.9M | −$12.0M | −$7.1M | −$2.2M | −$67,993 |
| EBITDA | −$10.4M | −$8.0M | −$8.5M | −$7.0M | −$2.2M | −$67,629 |
| EPS (diluted) | −$0.41 | −$0.55 | −$0.73 | −$0.48 | −$0.15 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $11.2M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | $5.6M | — | $2.1M | $1.7M | $8.5M | — | — |
| Gross profit | — | — | — | — | — | $5.6M | — | −$2.1M | −$1.7M | −$8.5M | — | — |
| Research & development | $705,789 | $524,781 | $496,543 | $412,639 | $496,197 | $314,404 | $861,441 | $1.1M | $614,462 | $762,276 | $387,123 | $1.0M |
| Sales, general & admin | $450,330 | $578,698 | $5.3M | $904,346 | $1.0M | $1.5M | $1.6M | $1.0M | $1.1M | $1.0M | $2.7M | $2.1M |
| Total operating expenses | $1.2M | $1.1M | $5.8M | $1.3M | $1.5M | $1.8M | $2.4M | $2.1M | $1.7M | $1.8M | $3.1M | $3.2M |
| Operating income | −$1.2M | −$1.1M | −$5.8M | −$1.3M | −$1.5M | −$1.8M | −$2.4M | −$2.1M | −$1.7M | −$1.8M | −$3.1M | −$3.2M |
| Interest income | $35,130 | $44,909 | $53,170 | $15,697 | $8,495 | $21,421 | — | $37,752 | $39,397 | $50,416 | — | — |
| Interest expense | — | — | — | — | — | $115,253 | — | $37,752 | $39,397 | $2.7M | $2.7M | $427,732 |
| Income before taxes | −$1.2M | −$1.2M | −$6.0M | −$1.1M | −$1.5M | −$1.8M | −$2.4M | −$2.0M | −$1.7M | −$1.7M | −$5.8M | −$3.6M |
| Income taxes | — | — | — | — | — | $1.8M | — | — | −$1.7M | −$3,056 | — | −$3,160 |
| Net income | −$1.2M | −$1.2M | −$6.0M | −$1.1M | −$1.5M | −$1.8M | −$2.4M | −$2.0M | −$1.7M | −$1.7M | −$5.8M | −$3.6M |
| EBITDA | −$1.2M | −$1.2M | −$6.0M | −$1.1M | −$1.5M | −$1.8M | −$2.4M | −$2.1M | −$1.7M | −$1.7M | — | −$3.2M |
| EPS (diluted) | −$0.03 | −$0.03 | −$0.14 | −$0.07 | −$0.09 | −$0.11 | −$0.17 | −$0.14 | −$0.11 | −$0.12 | −$0.37 | −$0.26 |
| Gross margin | — | — | — | — | — | 50.0% | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −16.2% | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | −16.0% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MIRA's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MIRA financial results
MIRA Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $10.4 million. Diluted earnings per share came to −$0.41.
See the MIRA stock overview for the latest quote and news, or the MIRA chart for price history and technical indicators.
MIRA income statement FAQ
Does MIRA Pharmaceuticals have revenue?
MIRA Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is MIRA Pharmaceuticals profitable?
No. MIRA Pharmaceuticals reported a net loss of $10.4 million in fiscal 2025.
How much does MIRA Pharmaceuticals spend on research and development?
MIRA Pharmaceuticals spent $1.7 million on research and development in fiscal 2025.
What are MIRA Pharmaceuticals's earnings per share?
MIRA Pharmaceuticals earned $-0.41 per diluted share in fiscal 2025, compared with $-0.55 a year earlier.
When will MIRA Pharmaceuticals report its next earnings?
MIRA Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does MIRA Pharmaceuticals's fiscal year end?
MIRA Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.